Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Current Role

Christian Chaussy, Derya Tilki, Stefan Thüroff

Department of Urology, Klinikum Harlaching, Munich, Germany.
Department of Urology, Ludwig-Maximilians-University, Munich, Germany.
Harlachinger Krebshilfe e.V., Munich, Germany.

DOI: 10.4236/jct.2013.44A007                

Abstract

Over the past 25 years, the average life expectancy for men has increased by 4 years, and the age of prostate cancer detection has decreased an average of 10 years with diagnosis increasingly made at early-stage disease where curative therapy is possible. These changing trends in the age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of aggressive cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient quality of life (QOL). Greater awareness of the shortcomings in radical prostatectomy, external radiotherapy and brachytherapy have prompted the search for alternative curative therapies that offer comparable rates of cancer control and less treatment-related morbidity to better preserve QOL. High intensity focused ultrasound (HIFU) possesses characteristics that make it an attractive curative therapy option. HIFU is a non-invasive approach that uses precisely-delivered ultrasound energy to achieve tumor cell necrosis without radiation or surgical excision. In current urological oncology, HIFU is used clinically in the treatment of prostate cancer, and is under experimental investigation for therapeutic use in renal and breast malignancies. Clinical research on HIFU therapy for localized prostate cancer began in the 1990s, and there have now been approximately 30,000 prostate cancer patients treated with HIFU, predominantly with the Ablatherm (EDAP TMS, Lyon, France) device. Transurethral resection of the prostate (TURP) has been combined with HIFU since 2000 to reduce prostate size, facilitate tissue destruction, and to minimize side effects. Advances in imaging technologies are expected to further improve the already superior efficacy and morbidity outcomes, and ongoing investigation of HIFU as a focal therapy and in salvage and palliative indications are serving to expand the role of HIFU as a highly versatile non-invasive therapy for prostate cancer.

Keywords

High Intensity Focused Ultrasound (HIFU); PCa Therapy Non-Invasive; Focal Therapy Hormone Resistant PCa

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	C. G. Chaussy, “Ultrasonidos De Alta Intensidad Focalizados (HIFU) Para el Tratamiento Local del Cancer de Prostata: Papel Actual,” Archivos Espa?oles de Urología, Vol. 64, No. 6, 2011, pp. 493-506.
[2]	C. H. Chaussy and S. Thuroff, “The Status of High-Intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer and the Impact of a Combined Resection,” Current Urology Reports, Vol. 4, No. 3, 2003, pp. 248-252. doi:10.1007/s11934-003-0077-0
[3]	C. Chaussy and S. Thuroff, “Results and Side Effects of High Intensity Focused Ultrasound in Localized Prostate Cancer,” Journal of Endourology, Vol. 15, No. 4, 2001, pp. 437-440, 447-448. doi:10.1089/089277901300189501
[4]	Ch. Chaussy and S. Thuroff, “The Use of High-Intensity Focused Ultrasound in Prostate Cancer,” In: O Ukimura and I. S. Gill, Eds., Contemporary Interventional Ultrasonography in Urology, Springer, London, 2009, pp. 63-74. doi:10.1007/978-1-84800-217-3_7
[5]	A. Blana, F. J. Murat, B. Walter, S. Thuroff, W. F. Wieland, C. Chaussy and A. Gelet, “First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer,” European Urology, Vol. 53, No. 6, 2008, pp. 1194-1201. doi:10.1016/j.eururo.2007.10.062
[6]	L. Poissonnier, A. Gelet, J. Y. Chapelon, R. Bouvier, O. Rouviere, C. Pangaud, D. Lyonnet and J. M. Dubernard, “Results of Transrectal Focused Ultrasound for the Treatment of Localized Prostate Cancer (120 Patients with PSA < or +10 ng/ml),” Progres en Urologie, Vol. 13, 2003, pp. 60-72.
[7]	J. G. Lynn and T. J. Putman, “Histological and Cerebral Lesions Produced by Focused Ultrasound,” American Journal of Pathology, Vol. 20, No. 3, 1944, pp. 637-649.
[8]	G. ter Haar, “Intervention and Therapy,” Ultrasound in Medicine & Biology, Vol. 23, Suppl. 1, 2000, pp. S51-54. doi:10.1016/S0301-5629(00)00164-2
[9]	C. G. Chaussy and S. F. Thüroff, “Robotic High-Intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?” Current Urology Reports, Vol. 12, No. 3, 2011, pp. 180-187. doi:10.1007/s11934-011-0184-2
[10]	C. Chaussy and S. Thüroff, “High-Intensity Focused Ultrasound in the Management of Prostate Cancer,” Expert Review of Medical Devices, Vol. 7, No. 2, 2010, pp. 209-217. doi:10.1586/erd.09.66
[11]	J. Y. Chapelon, J. Margonari, Y. Theillère, F. Gorry, F. Vernier, E. Blanc and A. Gelet, “Effects of High-Energy Focused Ultrasound on Kidney Tissue in the Rat and the Dog,” European Urology, Vol. 22, No. 2, 1992, pp. 147-152.
[12]	T. Uchida, N. T. Sanghvi, T. A. Gardner, M. O. Koch, D. Ishii, S. Minei, T. Satoh, T. Hyodo, A. Irie and S. Baba, “Transrectal High-Intensity Focused Ultrasound for Treatment of Patients with Stage T1b-2n0m0 Localized Prostate Cancer: A Preliminary Report,” Urology, Vol. 59, No. 3, 2002, pp. 394-398; Discussion pp. 398-399. doi:10.1016/S0090-4295(01)01624-7
[13]	J. Y. Chapelon, D. Cathignol, C. Cain, E. Ebbini, J. U. Kluiwstra, O. A. Sapozhnikov, G. Fleury, R. Berriet, L. Chupin and J. L. Guey, “New Piezoelectric Transducers for Therapeutic Ultrasound,” Ultrasound in Medicine & Biology, Vol. 26, No. 1, 2000, pp. 153-159. doi:10.1016/S0301-5629(99)00120-9
[14]	L. Curiel, F. Chavrier, R. Souchon, A. Birer and J. Y. Chapelon, “1.5-D High Intensity Focused Ultrasound Array for Non-Invasive Prostate Cancer Surgery,” IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, Vol. 49, No. 2, 2002, pp. 231-242. doi:10.1109/58.985707
[15]	J. S. Tan, L. A. Frizzell, N. T. Sanghvi, R. Seip, J. S. Wu and J. T. Kouzmanoff, “Design of Focused Ultrasound Phased Arrays for Prostate Treatment,” IEEE Ultrasonics Symposium, Vol. 2, 2000, pp. 1247-1251.
[16]	G. O. Oosterhof, E. B. Cornel, G. A. Smits, F. M. Debruyne and J. A. Schalken, “Influence of High Intensity Focused Ultrasound on the Development of Metastases,” European Urology, Vol. 32, No. 1, 1997, pp. 91-95.
[17]	R. S. Foster, R. Bihrle, N. Sanghvi, F. Fry, K. Kopecky, J. Regan, J. Eble, C. Hennige, L. V. Hennige and J. P. Donohue, “Production of Prostatic Lesions in Canines Using Transrectally Administered High Intensity Focused Ultrasound,” European Urology, Vol. 23, No. 2, 1993, pp. 330-336.
[18]	A. Gelet, J. Y. Chapelon, J. Margonari, Y. Theillere, F. Gorry, D. Cathignol and E. Blanc, “Prostatic Tissue Destruction by High-Intensity Focused Ultrasound: Experimentation on Canine Prostate,” Journal of Endourology, Vol. 7, No. 3, 1993, pp. 249-253. doi:10.1089/end.1993.7.249
[19]	C. Chaussy, S. Thüroff, X. Rebillard and A. Gelet, “Technology Insight: High-Intensity Focused Ultrasound for Urologic Cancers,” Nature Clinical Practice Urology, Vol. 2, No. 4, 2005, pp. 191-198. doi:10.1038/ncpuro0150
[20]	X. Rebillard, J. L. Davin and M. Soulié, “Comité de Cancérologie de l’Association Fran?aise d’Urologie. Treatment by HIFU of Prostate Cancer: Survey of Literature and Treatment Indications,” Progrès en Urologie, Vol. 13, No. 6, 2003, pp. 1428-1456.
[21]	C. G. Chaussy and S. Thüroff, “Robot-Assisted HighIntensity Focused Ultrasound in Focal Therapy of Prostate Cancer,” Journal of Endourology, Vol. 24, No. 5, 2010, pp. 843-847. doi:10.1089/end. 2009.0439
[22]	Misonix/US HIFU, “HIFU with the Sonablate 5000,” 2011. http://www.ushifu.com/
[23]	H. P. Beerlage, G. J. van Leenders, G. O. Oosterhof, J. A. Witjes, E. T. Ruijter, C. A. van de Kaa, F. M. Debruyne and J. J. de la Rosette, “High-Intensity Focused Ultrasound (HIFU) Followed after One to Two Weeks by Radical Retropubic Prostatectomy: Results of A Prospective Study,” Prostate, Vol. 39, No. 1, 1999, pp. 41-46.
[24]	O. Rouviere, D. Lyonnet, A. Raudrant, C. Colin-Pangaud, J. Y. Chapelon, R. Bouvier, J. M. Dubernard and A. Gelet, “MRI Appearance of Prostate Following Transrectal HIFU Ablation of Localized Cancer,” European Urology, Vol. 40, No. 3, 2001, pp. 265-274. doi:10.1159/000049786
[25]	K. Hynynen, W. R. Freund, H. E. Cline, A. H. Chung, R. D. Watkins, J. P. Vetro and F. A. Jolesz, “A Clinical, Noninvasive, MR Imaging-Monitored Ultrasound Surgery Method,” Radiographics, Vol. 16, No. 1, 1996, pp. 185-195.
[26]	C. Damianou, M. Pavlou, O. Velev, K. Kyriakou and M. Trimikliniotis, “High Intensity Focused Ultrasound Ablation of Kidney Guided by MRI,” Ultrasound in Medicine & Biology, Vol. 30, No. 3, 2004, pp. 397-404. doi:10.1016/j.ultrasmedbio.2003.10.018
[27]	T. Wu, J. P. Felmlee, J. F. Greenleaf, S. J. Riederer and R. L. Ehman, “Assessment of Thermal Tissue Ablation with MR Elastography,” Magnetic Resonance in Medicine, Vol. 45, No. 1, 2001, pp. 80-87. doi:10.1002/1522-2594(200101)45:1<80::AID-MRM1012>3.0.CO;2-Y
[28]	S. Vaezy, X. Shi, R. W. Martin, E. Chi, P. I. Nelson, M. R. Bailey and L. A. Crum, “Real-Time Visualization of High-Intensity Focused Ultrasound Treatment Using Ultrasound Imaging,” Ultrasound in Medicine & Biology, Vol. 27, No. 1, 2001, pp. 33-42. doi:10.1016/S0301-5629(00)00279-9
[29]	J. P. Sedelaar, R. G. Aarnink, G. J. van Leenders, H. P. Beerlage, F. M. Debruyne, H. Wijkstra and J. J. de La Rosette, “The Application of Three-Dimensional Contrast-Enhanced Ultrasound to Measure Volume of Affected Tissue after HIFU Treatment for Localized Prostate Cancer,” European Urology, Vol. 37, No. 5, 2000, pp. 559-568. doi:10.1159/000020193
[30]	J. Lu, H. Ying, Z. Sun, M. Motamedi, B. Bell and L. C. Sheppard, “In Vitro Measurement of Speed of Sound during Coagulate Tissue Heating,” Ultrasonics Symposium Proceedings, Vol. 2, 1996, pp. 1299-1302.
[31]	A. Gelet, J. Y. Chapelon, L. Poissonnier, R. Bouvier, O. Rouvière, L. Curiel, M. Janier and G. Vallancien, “Local Recurrence of Prostate Cancer after External Beam Radiotherapy: Early Experience of Salvage Therapy Using High-Intensity Focused Ultrasonography,” Urology, Vol. 63, No. 4, 2004, pp. 625-629.
[32]	C. Chaussy and S. Thueroff, “Complete Remission in Metastatic Prostate Cancer after Combined Local and Systemic Therapy,” Urology, Vol. 68, 2006, pp. 197-198. doi:10.1016/j. urology.2006.08.631
[33]	V. Ficarra, S. Z. Antoniolli, G. Novara, A. Parisi, S. Fracalanza, G. Martignoni and W. Artibani, “Short-Term Outcome after High-Intensity Focused Ultrasound in the Treatment of Patients with High-Risk Prostate Cancer,” BJU International, Vol. 98, No. 6, 2006, pp. 1193-1198. doi:10.1111/j.1464-410X.2006.06561.x
[34]	ASTRO, “Consensus Statement: Guidelines for PSA Following Radiation Therapy,” International Journal of Radiation Oncology, Biology, Physics, Vol. 37, No. 5, 1997, pp. 1035-1041.
[35]	C. G. Chaussy and S. Thueroff, “Transrectal High-Intensity Focused Ultrasound for Local Treatment of Prostate Cancer,” Urologe A, Vol. 48, No. 7, 2009, pp. 710-718.
[36]	G. Vallancien, D. Prapotnich, X. Cathelineau, H. Baumert and F. Rozet, “Transrectal Focused Ultrasound Combined with Transurethral Resection of the Prostate for the Treatment of Localized Prostate Cancer: Feasibility Study,” Journal of Urology, Vol. 171, No. 6, 2004, pp. 2265-2267.
[37]	P. K. Agarwal, N. Sadetsky, B. R. Konety, M. I. Resnick and P. R. Carroll, “Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment Failure after Primary and Salvage Therapy for Prostate Cancer: Likelihood, Patterns of Care, and Outcomes,” Cancer, Vol. 112, No. 2, 2008, pp. 307-314. doi:10.1002/cncr.23161
[38]	A. Gelet, J. Y. Chapelon, R. Bouvier, R. Souchon, C. Pangaud, A. F. Abdelrahim, D. Cathignol and J. M. Dubernard, “Treatment of Prostate Cancer with Transrectal Focused Ultrasound: Early Clinical Experience,” European Urology, Vol. 29, No. 2, 1996, pp. 174-183.
[39]	A. Gelet, J. Y. Chapelon, R. Bouvier, C. Pangaud and Y. Lasne, “Local Control of Prostate Cancer by Transrectal High Intensity Focused Ultrasound Therapy: Preliminary Results,” Journal of Urology, Vol. 161, No. 1, 1999, pp. 156-162. doi:10.1016/S0022-5347(01)62087-1
[40]	A. Gelet, J. Y. Chapelon, R. Bouvier, O. Rouvière, Y. Lasne, D. Lyonnet and J M. Dubernard, “Transrectal HighIntensity Focused Ultrasound: Minimally Invasive Therapy of Localized Prostate Cancer,” Journal of Endourology, Vol. 14, No. 6, 2000, pp. 519-528. doi:10.1089/end.2000.14.519
[41]	P. Richaud, J. L. Moreau, P. Beuzeboc, X. Rébillard, A. Villers, M. Peyromaure, F. Cornud, M. Soulié and J. L. Davin, “Follow-Up of Prostate Cancer. Guidelines of the French Urological Association Oncology Committee,” Progres en Urologie, Vol. 15, 2005, pp. 586-592.
[42]	A. Gelet, J. Y. Chapelon, R. Bouvier, O. Rouvière, D. Lyonnet and J. M. Dubernard, “Transrectal High Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Factors Influencing the Outcome,” European Urology, Vol. 40, No. 2, 2001, pp. 124-129. doi:10.1159/000049761
[43]	A. Blana, S. Rogenhofer, R. Ganzer, J. C. Lunz, M. Schostak, W. F. Wieland and B. Walter, “Eight Years’ Experience with High-Intensity Focused Ultrasonography for Treatment of Localized Prostate Cancer,” Urology, Vol. 72, No. 6, 2008, pp. 1329-1333. doi:10.1016/j.urology.2008.06.062
[44]	L. Poissonnier, J. Y. Chapelon, O. Rouvière, L. Curiel, R. Bouvier, X. Martin, J. M. Dubernard and A. Gelet, “Control of Prostate Cancer by Transrectal HIFU in 227 Patients,” European Urology, Vol. 51, No. 2, 2007, pp. 381-387. doi:10.1016/j.eururo.2006.04.012
[45]	A. Blana, S. C. W. Brown, C. Chaussy, G. N. Conti, J. A. Eastham, R. Ganzer, F. J. Murat, X. Rebillard, J. C. Rewcastle, C. N. Robertson, S. Thueroff, J. F. Ward and A. Gelet, “Primary Prostate HIFU without Pretreatment Hormone Therapy: Biochemical Survival of 763 Patients Tracked with the @-Registry,” European Urology Supplements, Vol. 8, No. 4, 2009, p. 333. doi:10.1016/S1569-9056(09)60838-1
[46]	A. V. D’Amico, J. Moul, P. R. Carroll, L. Sun, D. Lubeck and M. H. Chen, “Cancer-Specific Mortality after Surgery or Radiation for Patients with Clinically Localized Prostate Cancer Managed During the Prostate Specific Antigen Era,” Journal of Clinical Oncology, Vol. 21 No. 11, 2003, pp. 2163-2172. doi:10.1200/JCO.2003.01.075
[47]	R. Ganzer, S. Rogenhofer, B. Walter, J. C. Lunz, M. Schostak, W. F. Wieland and A. Blana, “PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focused Ultrasound (HIFU) Treatment of Localized Prostate Cancer,” European Urology, Vol. 53, No. 3, 2008, pp. 547-553. doi:10.1016/j.eururo.2007.07.010
[48]	S. Thüroff, C. Chaussy, G. Vallancien, W. Wieland, H. J. Kiel, A. Le Duc, F. Desgrandchamps, J. J. De La Rosette and A. Gelet, “High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study,” Journal of Endourology, Vol. 17, No. 8, 2003, pp. 673-677. doi:10.1089/089277903322518699
[49]	P. A. Kupelian, M. Elshaikh, C. A. Reddy, C. Zippe and E. A. Klein, “Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single Institution Experience with Radical Prostatectomy and External-Beam Radiotherapy,” Journal of Clinical Oncology, Vol. 20, No. 16, 2002, pp. 3376-3385. doi:10.1200/JCO.2002.01.150
[50]	D. A. Kuban, M. Elshaikh, C. A. Reddy, C. Zippe and E. A. Klein, “Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era,” International Journal of Radiation Oncology, Biology, Physics, Vol. 57, No. 4, 2003, pp. 915-928. doi:10.1016/S0360-3016(03)00632-1
[51]	L. Potters, E. A. Klein, M. W. Kattan, C. A. Reddy, J. P. Ciezki, A. M. Reuther and P. A. Kupelian, “Monotherapy for Stage T1-T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Seed Implantation,” Radiotherapy and Oncology, Vol. 71, No. 1, 2004, pp. 29-33. doi:10.1016/j.radonc.2003.12.011
[52]	S. Crouzet, X. Rebillard, D. Chevallier, P. Rischmann, G. Pasticier, G. Garcia, O. Rouviere, J. Y. Chapelon and A. Gelet, “Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 Patients,” European Urology, Vol. 58, No. 4, 2010, pp. 559-566. doi:10.1016/j.eururo.2010.06.037
[53]	C. G. Chaussy and S. Thüroff, “High-Intensive Focused Ultrasound in Localized Prostate Cancer,” Journal of Endourology, Vol. 14, No. 3, 2000, pp. 293-299. doi:10.1089/end.2000.14.293
[54]	S. Thüroff and C. G. Chaussy, “High-Intensity Focused Ultrasound: Complications and Adverse Events,” Molecular Urology, Vol. 4, No. 3, 2000, pp. 183-187.
[55]	S. Thüroff, “High-Intensity Focused Ultrasound for Prostate Cancer,” In: L.-M. Su and Stephen C. Young, Eds., Early Diagnosis and Treatment of Cancer: Prostate Cancer, Saunders Elsevier, Missouri, 2008, pp. 177-192.
[56]	S. Thuaroff, C. Chaussy and A. Gelet, “Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer. Energy/Efficacy Correlation. WCE Congress, 2001,” Journal of Endourology, Vol. 15, Suppl. 1, 2001, p. S32 (Abstract A3-P10).
[57]	C. G. Chaussy and S. F. Thueroff, “HIFU Treatment of Locally Advanced Prostate Cancer,” Journal of Endourology, Vol. 24, Suppl. 1, 2010, p. PS12-2.
[58]	C. Chaussy, S. Thuroff and R. Nanieva, “Hormone Resistant Prostate Cancer Treated by Robotic High Intensive Ultrasound,” Journal of Urology, Vol. 183, 2010, Article ID: e262.
[59]	C. Chaussy, S. Thüroff and T. Bergsdorf, “Local Recurrence of Prostate Cancer after Curative Therapy. HIFU (Ablatherm) as a Treatment Option,” Urologe A, Vol 45, No. 10, 2006, pp. 1271-1275. doi:10.1007/s00120-006-1214-4
[60]	F. J. Murat, L. Poissonnier, M. Rabilloud, A. Belot, R. Bouvier, O. Rouviere, J. Y. Chapelon and A. Gelet, “MidTerm Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer,” European Urology, Vol. 55, No. 3, 2009, pp. 640-647. doi:10.1016/j.eururo.2008.04.091
[61]	V. Berge, E. Baco and S. J. Karlsen, “A Prospective Study of Salvage High Intensity Focused Ultrasound for Locally Radiorecurrent Prostate Cancer: Early Results,” Scandinavian Journal of Urology, Vol. 44, No. 4, 2010, pp. 223-227.
[62]	M. Hayashi, S. Shinmei and K. Asano, “Transrectal HighIntensity Focused Ultrasound for Treatment for Patients with Biochemical Failure after Radical Prostatectomy,” International Journal of Urology, Vol. 14, No. 11, 2008, pp. 1048-1050.
[63]	M. Marberger, “Prostate Cancer 2008 Challenges in Diagnostic and Management,” European Urology, Vol. 8, Suppl. 3, 2009, pp. 1989-1996.
[64]	P. J. van Leeuwen, D. Connolly, T. L. Tammela, A. Auvinen, R. Kranse, M. J. Roobol, F. H. Schroder and A. Gavin, “Balancing the Harms and Benefits of Early Detection of Prostate Cancer,” Cancer, Vol. 116, 2010, No. 20, pp. 4857-4865.
[65]	L. Klotz, “Active Surveillance for Prostate Cancer: For Whom?” Journal of Clinical Oncology, Vol. 23, No. 32, 2005, pp. 8165-8169. doi:10.1200/JCO.2005.03.3134
[66]	S. Roemeling, M. J. Roobol, M. W. Kattan, T. H. van der Kwast, E. W. Steyerberg and F. H. Schr?der, “Nomogram Use for the Prediction of Indolent Prostate Cancer: Impact on Screen-Detected Populations,” Cancer, Vol. 110, No. 10, 2007, pp. 2218-2221.
[67]	G. Onik and W. Barzell, “Transperineal. 3D Mapping Biopsy of the Prostate: An Essential Tool in Selecting Patients for Focal Prostate Cancer Therapy,” Urologic Oncology, Vol. 26, No. 5, 2008, pp. 506-510. doi:10.1016/j.urolonc.2008.03.005
[68]	O. Rouvière, R. Souchon, R. Salomir, A. Gelet, J. Y. Chapelon and D. Lyonnet, “Transrectal High-Intensity Focused Ultrasound Ablation of Prostate Cancer: Effective Treatment Requiring Accurate Imaging,” European Journal of Radiology, Vol. 63, No. 3, 2007, pp. 317-327. doi:10.1016/j.ejrad.2007.06.026
[69]	A. P. Kirkham, M. Emberton and C. Allen, “How Good Is MRI at Detecting and Characterising Cancer within the Prostate?” European Urology, Vol. 50, No. 6, 2006, pp. 1163-1174.
[70]	J. K. Kim, S. S. Hong, Y. J. Choi, S. H. Park, H. Ahn, C. S. Kim and K. S. Cho, “Wash-In Rate on the Basis of Dynamic Contrast-Enhanced MRI: Usefulness for Prostate Cancer Detection and Localization,” Journal of Magnetic Resonance Imaging, Vol. 22, No. 5, 2005, pp. 639-646. doi:10.1002/jmri.20431
[71]	M. A. Haider, T. H. van der Kwast, J. Tanguay, A. J. Evans, A. T. Hashmi, G. Lockwood and J. Trachtenberg, “Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer,” American Journal of Roentgenology, Vol. 189, No. 2, 2007, pp. 323-328. doi:10.2214/AJR.07.2211
[72]	T. Uchida, R. O. Illing, P. J. Cathcart and M. Emberton, “To What Extent does the Prostate-Specific Antigen Nadir Predict Subsequent Treatment Failure after Transrectal High-Intensity Focused Ultrasound Therapy for Presumed Localized Adenocarcinoma of the Prostate,” BJU International, Vol. 98, No. 3, 2006, pp. 537-539.
[73]	F. Wu, Z. B. Wang, P. Lu, Z. L. Xu, W. Z. Chen, H. Zhu and C. B. Jin, “Activated Anti-Tumor Immunity in Cancer Patients after High Intensity Focused Ultrasound Ablation,” Ultrasound in Medicine and Biology, Vol. 30, No. 9, 2004, pp. 1217-1222. doi:10.1016/j.ultrasmedbio.2004.08.003
[74]	F. Wu, Z. B. Wang, Y. D. Cao, Q. Zhou, Y. Zhang, Z. L. Xu and X. Q. Zhu, “Expression of Tumor Antigens and Heat-Shock Protein 70 in Breast Cancer Cells after High Intensity Focused Ultrasound Ablation,” Annals of Surgical Oncology, Vol. 14, No. 3, 2007, pp. 1237-1242. doi:10.1245/s10434-006-9275-6
[75]	Z. Hu, X. Y. Yang, Y. Liu, G. N. Sankin, E. C. Pua, M. A. Morse, H. K. Lyerly, T. M. Clay and P. Zhong, “Investigation of HIFU-Induced Antitumor Immunity in a Murine Tumor Model,” Journal of Translational Medicine, Vol. 5, 2007, p. 34.
[76]	P. Lu, X. Q. Zhu, Z. L. Xu, Q. Zhou, J. Zhang and F. Wu, “Increased Infiltration of Activated Tumor Infiltrating Lymphocytes after High Intensity Focused Ultrasound Ablation of Human Breast Cancer,” Surgery, Vol. 145, No. 3, 2009, pp. 286-293. doi:10.1016/j.surg.2008.10.010
[77]	H. M. Lee, J. H. Hong and H. Y. Choi, “High-Intensity Focused Ultrasound Therapy for Clinically Localized Prostate Cancer,” Prostate Cancer and Prostatic Diseases, Vol. 9, No. 4, 2006, pp. 439-443. doi:10.1038/sj.pcan.4500901